

REC No	IRAS No	Name of Trial	Date of First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for not achieving the 70 day benchmark										Reasons for delay correspond to:
												A	B	C	D	E	F	G	H	I	J	
												Permissions delayed/denied	Suspended by sponsor	Closed by sponsor	Sponsor Delays	Staff availability issues	No patients seen	No patients consented	Contracting delays	Rare diseases	Other	
14/LO/1486	159398	A Phase 1b/3, Multicentre, Open-label Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)		Within 70 Days	12/10/2016	05/06/2017	07/04/2016	06/06/2017	09/06/2017			09/06/2017										
13/SC/0645	143871	Pre-eclampsia in Hospital: Early Induction or Expectant Management	17/02/2017	No	26/05/2016	29/09/2016	15/06/2016	23/01/2017	07/02/2017			07/02/2017		Y								Sponsor
15/LO/1506	164622	IMRIS: Phase II study of IMRT in primary bone and soft tissue sarcoma	14/03/2017	No	09/06/2016	03/10/2016	15/06/2016	20/01/2017	05/01/2017			06/01/2017	Y		Y		Y	Y				Sponsor
15/WM/0261	183481	Anticoagulants for Living FoEtuses in women with recurrent miscarriage and inherited thrombophilia : ALIFE 2	25/04/2017	No	04/02/2016	16/08/2016	15/06/2016	06/12/2016	12/12/2016			12/12/2016					Y	Y				Neither
16/EE/0196	201273	CHIL 5025, A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10mg in T2DM Patients aged 10 - 24 years.?		No	01/07/2016	28/07/2016	20/07/2016	08/09/2016	13/10/2016			13/10/2016	Y					Y				Sponsor
15/SC/0700	192904	Clinical Study Protocol M13-549A Phase 3, randomized, double-blind study comparing ABT-494 to placebo in subjects with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (sDMARDs) and have an inadequate response to sDMARDs		No	14/06/2016	06/12/2016	06/12/2016	28/11/2016	06/01/2017			06/01/2017						Y		Y		Neither
15/NS/0070	183761	Multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to atherosclerotic femoro-popliteal, with or without infra-popliteal involvement, peripheral arterial disease	08/03/2017	No	08/06/2016	13/07/2016	27/04/2016	26/10/2016	16/12/2016			16/12/2016							Y			Sponsor
17/WM/0011	219130	A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy		Within 70 Days	30/03/2016	07/06/2017	19/04/2017	17/05/2017	08/06/2017			08/06/2017										
16/WM/0001	190802	World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip	31/10/2016	No	21/06/2016	05/08/2016	20/06/2016	05/08/2016	06/09/2016			06/09/2016							Y			Neither
16/LO/0087	183136	A Single arm open labeled multicentre phase 1b dose escalation study of carfilzomib taken in combination with Thalidomide and Dexamethasone in relapsed AL amyloidosis (CATALYST trial).		No	12/04/2016	27/09/2016	09/08/2016	12/10/2016	18/10/2016			18/10/2016			Y		Y					Sponsor
16/LO/1386	199366	A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Emapipretide in Patients Hospitalized with Severe Congestion due to Heart Failure	04/05/2017	No	28/04/2016	14/11/2016	14/11/2016	15/02/2017	21/02/2017			21/02/2017			Y		Y					Sponsor
16/WM/0317	206807	Randomized Efficacy and Safety Trial with Oral S44819 after recent ischaemic cerebral event.International, multi-centre, randomized, double-blind placebo-controlled phase II study.	21/02/2017	No	13/05/2016	07/12/2016	07/10/2016	24/10/2016	02/02/2017			02/02/2017							Y			Sponsor
15/LO/1681	185104	A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib, 150 mg twice daily for 52 weeks (with follow up until last patient out up to a maximum of 2 years) in patients with ?Systemic Sclerosis associated interstitial lung disease		Within 70 Days	30/03/2017	08/06/2017	07/06/2016	24/05/2017	26/06/2017			26/06/2017										
16/LO/0853	201430	A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to Fc RIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.		No	05/05/2016	19/08/2016	19/08/2016	03/11/2016	14/11/2016			14/11/2016	Y					Y				Sponsor
16/LO/1822	212944	A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction (HFREF) - Vericiguat gObal study in subjects with heart failure and Reduced ejection fraction (VICTORIA)		No	15/09/2016	23/02/2017	07/12/2016	07/02/2017	08/03/2017			08/03/2017							Y			Neither
16/NE/0236	204005	Can a commercial activity monitor be used to effectively prescribe exercise and increase physical activity levels in chronic respiratory patients undertaking outpatient pulmonary rehabilitation? ? A feasibility study	13/12/2016	Yes	11/10/2016	11/10/2016	11/10/2016	10/11/2016	10/11/2016			10/11/2016							Y			Neither

REC No	IRAS No	Name of Trial	Date of First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for not achieving the 70 day benchmark										Reasons for delay correspond to:	
												A	B	C	D	E	F	G	H	I	J		
												Permissions delayed/denied	Suspended by sponsor	Closed by sponsor	Sponsor Delays	Staff availability issues	No patients seen	No patients consented	Contracting delays	Rare diseases	Other		
16/LO/1717	212505	A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia		No	06/10/2016	17/03/2017	07/11/2016	24/03/2017	05/04/2017						Y					Y		Neither	
16/EM/0219	204619	Female Aneuploidy screening Study (FAST)	09/11/2016	No	28/04/2016	12/07/2016	26/07/2016	12/07/2016	20/07/2016												Y	Neither	
16/WM/0118	182909	Sentimag along with routine technique in detection of Sentinel node biopsy		No	22/09/2016	10/03/2017	05/07/2016	28/03/2017	21/03/2017					Y								Sponsor	
16/SS/0074	196616	Randomised controlled trial of the use of a smart phone based event recorder versus standard care for patients presenting to the Emergency Department with palpitations and pre-syncope (The IPED study)	15/05/2017	No	14/10/2016	29/12/2016	28/12/2016	29/12/2016	21/02/2017			Y				Y						Sponsor	
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	15/05/2017	No	15/11/2016	31/01/2017	30/01/2017	07/03/2017	17/03/2017					Y							Y	Sponsor	
16/EM/0488	210608	A randomised controlled trial to investigate the effect of a structured education programme on women who have had gestational diabetes and are at risk of developing type 2 diabetes.	04/05/2017	Yes	03/11/2016	08/03/2017	01/03/2017	31/03/2017	31/03/2017												Y	Neither	
16/WM/0505	211350	Promoting physical activity through group self-management support for those with multi-morbidity: a randomised clinical trial		No	01/12/2016	21/03/2017	21/03/2017	01/12/2016	07/04/2017													Y	Neither
17/EM/0003	210798	Patient Input Monitoring of Pain in the Emergency Room: Novel Electronic Log (PIMPERNEL):feasibility study. A randomised controlled trial of an electronic pain score display in the emergency department.		No	12/03/2017	12/03/2017	24/02/2017	12/03/2017	08/06/2017					Y									Sponsor
16/NW/0629	211995	The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START): a randomised registry trial to assess the safety and efficacy of fluoxacillin as a longterm prophylaxis agent for infants with CF.		No	14/10/2016	16/11/2016	22/09/2016	17/01/2017	20/01/2017					Y									Sponsor
16/LO/1940	213099	AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT	21/02/2017	Yes	17/10/2016	05/01/2017	12/01/2017	30/01/2017	02/02/2017														
17/EM/0019	214674	Establishing normal ranges of microcirculatory function as determined by CytoCam- IDF imaging	16/03/2017	Yes	20/10/2016	24/01/2017	24/01/2017	25/01/2017	06/02/2017												Y	Neither	
17/YH/0120	208838	A pragmatic multi-centre randomised controlled non inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren's Contracture in adult patients		No	21/02/2017	06/04/2017	25/05/2017	21/06/2017	21/06/2017					Y									Sponsor
16/Wm/0463	210607	Developing and evaluating an education programme aimed at increasing physical activity in individuals with diagnosed coronary heart disease: a randomised controlled trial	16/03/2017	No	21/10/2016	22/12/2016	10/02/2017	21/12/2016	20/02/2017													Y	Sponsor
16/SC/0462	208830	DRAFFT 2 ? Distal Radius Fracture Fixation Trial 2	12/05/2017	No	08/06/2016	15/11/2016	11/11/2016	16/02/2017	03/04/2017					Y							Y	Sponsor	
16/LO/2078	213487	An open-label, multicentre, dose-escalation, phase Ia/Ib study to evaluate safety, pharmacokinetics and therapeutic activity of RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein-a (FAP), as a single agent (Part A) or in combination with trastuzumab or cetuximab following pretreatment with obinutuzumab (part B or C)		No	19/10/2016	03/02/2017	03/02/2017	08/02/2017	09/02/2017													Y	Sponsor
17/NE/0115	218417	Phase II study of Pirfenidone vs placebo in patients with fibrotic ILD that cannot be classified with moderate or high confidence into any other category of fibrotic IP by Multidisciplinary Team (MDT) review (?unclassifiable? ILD).		Within 70 Days	31/05/2017	16/06/2017	26/05/2017	06/06/2017	19/06/2017														
16/EM/0500	213455	Treatment of heart failure using indapamide: a pilot study of its effect on plasma FGF23	15/06/2017	No	13/10/2016	12/01/2017	14/02/2017	08/03/2017	08/03/2017												Y	Neither	
16/WS/0197	186191	ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer		No	09/12/2016	28/03/2017	01/02/2017	06/04/2017	20/04/2017													Y	Neither

